"versionIdentifier","uuid:ID","id","rationale","instanceType"
"2","ec4cb25b-9b7f-4ea2-9bd9-a876074517a0","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion"
